

# Swedish National Study on Aging and Care in Kungsholmen

<https://www.neurodegenerationresearch.eu/survey/swedish-national-study-on-aging-and-care-in-kungsholmen/>

## **Title of cohort**

Swedish National Study on Aging and Care in Kungsholmen

## **Acronym for cohort**

SNAC-K and SNAC-K MRI Study

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Laura

## **Name of Principal Investigator - Last name**

Fratiglioni

## **Address of institution -Institution**

Aging Research Center (ARC), NVS, KI

## **Address of institution - Street address**

Gävlegatan 16

## **Address of institution - City**

Stockholm

## **Address of institution - Postcode**

11330

## **Country**

Sweden

## **Website**

[www.snac-k.se](http://www.snac-k.se)

## **Contact email**

[email protected]

## **Funding source**

Swedish Government, VR

### **Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Alzheimer's disease and other dementias|Neurodegenerative disease in general

### **Q1b. When are studies on the above condition(s) expected to become possible?**

Already possible

### **Q2a. In a single sentence what is the stated aim of the cohort?**

To increase our understanding of the aging process and to identify preventive strategies that can lead to improved health and care of the elderly. I carry out several studies within SNAC-K: e.g., (1)Vascular risk factors and mechanisms of cognitive decline in aging; (2)Dementia trends over time; (3)Functional disability (might be due to brain degeneration) trend and determinants over time

### **Q2b. What distinguishes this cohort from other population cohorts?**

My research involves 2 distinguishes in this cohort: (1)epidemiological, clinical, and brain imaging data are integrated; (2)long-term follow-up that fits the need of studying health trends.

### **Q3a. i) Number of publications that involve use of your cohort to date**

100

### **Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

Wang R, Fratiglioni L, ..., Qiu C (PI). KI, Mixed brain pathologies mediate association between vascular factors and cognitive decline. *Alzheimers Dementia* 2016|Liang Y, ..., Qiu (PI). KI, Biological age in the association between BP and mortality. *Int J Cardiol* 2016|Ding M, Santoni G,..., Qiu C, ..., Fratiglioni L (PI). KI, Dementia trends in SNAC, 2010-2014 (ongoing) | Shakersain B Prudent diet may attenuate the adverse effects of Western diet on cognitive decline.| Wei-Li Xu HHEX\_23 AA Genotype Exacerbates Effect of Diabetes on Dementia and Alzheimer Disease: A Population-Based Longitudinal Study| Wei-Li Xu HHEX\_23 AA Genotype Exacerbates Effect of Diabetes on Dementia and Alzheimer Disease: A Population-Based Longitudinal Study

### **Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

Data are available on request. List of publication: <http://www.snac-k.se/publications/original->

articles/

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

60

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

103

**Q4b. Study criteria: what are the inclusion criteria?**

Eligible: community residence and institutionalized in Kungsholmen age 60+

**Q4c. Study criteria: what are the exclusion criteria?**

Language problem

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

1,000-5,000 participants

**Q6a. Please describe what measures are used to characterise participants**

multiple, e.g., global cognition, dementia, AD, ADL, etc. social interview, physical functioning, clinical examination, including geriatric, neurological and psychiatric assessment, cognitive assessment.

**Q6b. Are there additional measures for participants with a clinical disorder?**

CVD, diabetes, multimorbidity, etc. Proxy interview in case of cognitive impairment

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

No

**If yes please specify**

**Q7. What is the study design (select all that apply)?**

Prospective cohort|Longitudinal|Cross sectional survey

**Q8. Are your cases matched by**

Other health assessment

**Q9a. Does your study include a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. i) Please enter the data collection start date**

01/01/2001

**Q10a. ii) Please enter the data collection end date**

Ongoing

**Q10a. iii) Is data collection for this study**

Data collection ongoing|Data analysis ongoing

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

Yes - funding applied for/funding awarded

**Q11. Is data collected**

Through links to medical records

**Other please specify here**

linked to inpatient registry and death certificates

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

Yes (participants given permission to be re-contacted via PIs)

**Q13a. Please give information on the format and availability of data stored in a database (1)**

Data summarised in database

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (2)**

No

**% available**

**Q13a. Please give information on the format and availability of data stored in a database (3)**

Database on spreadsheet (e.g. excel)

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (4)**

Database on paper

**% available**

100

**Other (please specify)**

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

**% available**

100

**Q13b. Please give information on the format and availability of data held as individual records (2)**

No

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (3)**

Data held on computer based records

**% available**

100

**Q13b. Please give information on the format and availability of data held as individual records (4)**

No

**% available**

**Please specify language used**

Swedish, English

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Apply to PI or co-ordinator at resource| Access independent of collaboration with PI| Local/ regional access| National access| International access| Access restricted to peer-reviewed work| Resource has own ethics approval so usually no need for separate external ethics approval

**Q15. What data sharing policy is specified as a condition of use?**

Data made publicly available after a specified time point

**Q16a. Are tissues/samples/DNA available to other groups?**

Yes

**Q16b i) If yes, please describe below:**

Living donors: blood| Living donors: blood derivatives| Living donors: DNA

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples:(derivatives of primary samples)| Secondary samples: plasma| Secondary samples: DNA

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

Yes

**Q17. Is information on biological characteristics available to other groups?**

Yes, for all the cohort

**Number of Patients**  
**% of total cohort**

**Types:**

Population Cohorts

**Member States:**

Sweden

**Diseases:**

Alzheimer's disease & other dementias, Neurodegenerative disease in general

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A